Sankaran Vijay G, Weiss Mitchell J
1] Division of Hematology and Oncology, The Manton Center for Orphan Disease Research, Boston Children's Hospital, Boston, Massachusetts, USA. [2] Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA. [3] Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, Massachusetts, USA.
Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Nat Med. 2015 Mar;21(3):221-30. doi: 10.1038/nm.3814.
Anemia is a major source of morbidity and mortality worldwide. Here we review recent insights into how red blood cells (RBCs) are produced, the pathogenic mechanisms underlying various forms of anemia, and novel therapies derived from these findings. It is likely that these new insights, mainly arising from basic scientific studies, will contribute immensely to both the understanding of frequently debilitating forms of anemia and the ability to treat affected patients. Major worldwide diseases that are likely to benefit from new advances include the hemoglobinopathies (β-thalassemia and sickle cell disease); rare genetic disorders of RBC production; and anemias associated with chronic kidney disease, inflammation, and cancer. Promising new approaches to treatment include drugs that target recently defined pathways in RBC production, iron metabolism, and fetal globin-family gene expression, as well as gene therapies that use improved viral vectors and newly developed genome editing technologies.
贫血是全球发病和死亡的主要原因。在此,我们综述了关于红细胞(RBC)生成方式、各种贫血潜在致病机制以及基于这些发现的新型疗法的最新见解。这些主要源于基础科学研究的新见解,很可能极大地有助于理解常见的使人虚弱的贫血形式以及治疗受影响患者的能力。全球范围内可能受益于新进展的主要疾病包括血红蛋白病(β地中海贫血和镰状细胞病);罕见的红细胞生成遗传疾病;以及与慢性肾病、炎症和癌症相关的贫血。有前景的新治疗方法包括靶向最近确定的红细胞生成、铁代谢和胎儿珠蛋白家族基因表达途径的药物,以及使用改进的病毒载体和新开发的基因组编辑技术的基因疗法。